Your 510(k) clearance is invisible to the surgeon deciding between your device and a competitor with weaker evidence. That sentence reads as wrong to most MedTech executives, which is exactly why the problem has persisted for a decade and why it is getting worse.
It is getting worse because the evaluation is moving earlier. The surgeon who once formed an impression at a congress or through a representative now forms it alone, on a phone, from whatever your website and the wider web make available. By the time your commercial team is in the room, a position has usually already been taken.
Your website is trying to be two documents at once
Every website in a regulated vertical serves two readers with incompatible requirements. Almost every company builds thoroughly for one of them and treats the other as a courtesy.
The first reader: the regulator, or the internal function that anticipates one
This reader assesses what you claimed, what you proved, what you disclosed, and what you omitted. Every sentence is measured against the indication for use. In the United States that anchor is the
510(k) premarket notification, which establishes that a device is substantially equivalent to a legally marketed predicate and may therefore be marketed. It is a permission, not a persuasion.
This document is necessary. It is legally required. It is also, by design, the least persuasive artifact your company produces, because every element of it was written to survive challenge rather than to change a mind.
The second reader: the surgeon, arriving with eight minutes
This reader is not assessing your claims against your clearance. They are deciding whether adopting your device is worth the disruption to a workflow that currently functions and for which they are personally accountable.
They arrive on a mobile device, between clinical commitments, with a specific question. They will not navigate three levels deep. They will not download a PDF. They will form an impression in the time it takes to read one screen, and if that impression is that the page is talking to a regulator, they will leave.
These are different documents requiring different structures. Most MedTech companies have built the first one and are confused about why the second reader is not converting.
The five questions a surgeon is actually asking
Across commercial diagnostics in device and diagnostics companies, the same five questions surface repeatedly. None of them is answered by a clearance summary and none of them is a claim about efficacy.
1. Who else in my specialty is already using this
Adoption risk in surgery is social before it is clinical. A surgeon who adopts a device that nobody in their peer network uses carries the reputational exposure alone, and if a case goes badly the question will be why they chose an unusual instrument.
Named institutions and named specialties resolve this faster than any outcome data. The specificity matters more than the prestige: a community hospital surgeon is not reassured by a list of academic centres with different case mixes and different resourcing.
2. What happened in the cases that did not go well
The absence of failure cases reads as concealment rather than as safety. Experienced clinicians know that no device has an unbroken record and that the record you are showing them has been curated.
A company that names its failure modes, with the conditions under which they occur, is consistently read as more credible than one presenting an unblemished history. This is counterintuitive to marketing teams and obvious to clinicians.
3. What the learning curve costs me in operating room time
This is the most consequential unanswered question in MedTech commercial content. Operating room time is the scarcest resource in the buying decision, and every new device is slower for the first cases.
The surgeon is already assuming a learning curve exists. In the absence of data they will estimate it pessimistically, because the downside of underestimating it lands on them. Publishing an honest curve with context removes the largest single objection. Almost no company does, because the first-case number looks unflattering in isolation and nobody has been asked to contextualise it.
4. Who can I call who is not a sales representative
Peer reference is the highest-value asset in the buying process and the least likely to appear anywhere on a website. A named clinician at a named institution who has agreed to take calls converts at a rate no content asset approaches.
This is a relationship deliverable rather than a marketing one, which is precisely why it falls into the gap between functions and never gets built.
5. Whether the evidence is peer reviewed or sponsored, and how fast I can tell
Clinicians discount sponsored evidence, and they discount it more heavily when the sponsorship is difficult to determine. Industry payments to physicians are publicly searchable through the
CMS Open Payments database, so the relationship is discoverable whether or not you disclose it. Clear labelling of study funding is a trust signal. Burying it produces the opposite of the intended effect and is trivially detectable.
Your compliance team will approve all five
Here is where most commercial leaders have accepted a premise they have never tested. The assumption is that regulatory constraint prevents the website from answering these questions. In the majority of cases it does not.
None of the five requires a claim beyond the indication for use. Institutional adoption is a matter of fact. Failure modes are typically already documented in the instructions for use. Learning curve data is operational rather than clinical. Peer references are relationships. Funding disclosure is a transparency practice rather than a claim.
The constraint is real in specific cases and it is being used to explain a far larger absence than it accounts for. What is actually happening is that nobody has been asked to build the second document, so the review chain defaults to the most risk-averse position available, and that position is always regulatory.
Ask your regulatory lead a precise question rather than a general one. Not “can we talk about adoption” but “what specifically would be required for us to publish first-ten-case operating time alongside steady-state operating time.” The answer is frequently smaller than the assumption, and the conversation only happens if the question is specific.
Why this is an ownership problem, not a compliance problem
Somebody in your company owns regulatory approval by name. There is a person, a submission date, a document, and an accountability line that survives reorganization.
Name the person who owns surgeon trust.
In most MedTech companies the answer is a function rather than a person. Marketing owns it, which means nobody owns it, which means the artifact defaults to whoever in the review chain holds the strongest objection. That is the mechanism by which a website built to persuade ends up written to withstand audit.
This is a decision that was never consciously made, which is what makes it hard to see and easy to repeat. It is the same failure mode described in the
Judgment Layer: a call that carries real consequences, made by default rather than by anyone, with no named owner and therefore no possibility of review.
Treating it as an execution failure by the marketing team produces another year of the same outcome. The commercial evidence set has no owner, no budget line, and no deliverable date, so it does not exist. Everything downstream of that is a symptom.
What this costs, and where the cost hides
The loss here has the same property that makes AI citation gaps difficult to defend against: it does not appear in the CRM. A surgeon who reads your site, forms an unfavorable impression, and never contacts anyone generates no record, no reason code, and no line in the pipeline report.
What you see instead is a competitor with weaker clinical evidence winning accounts, and a commercial team that cannot explain why. The explanation is usually that the competitor answered questions three and four and you answered neither.
You can estimate the exposure. Take your close rate on opportunities where a surgeon requested a peer reference and you were able to provide one, against your close rate where you were not. Most companies have never segmented this, and the gap is usually large enough to fund the fix several times over.
What to do in the next thirty days
One. Watch a surgeon use your website
Not a usability panel. An actual surgeon, on a phone, given a real question and no instructions. Ten minutes of observation will tell you more than a quarter of analytics review, and it is the single most persuasive artifact you can bring to an internal argument about this.
Two. Score the site against the five questions
Count how many are answered on the page a surgeon would actually reach from a search or an AI answer, not somewhere in a resources section three clicks deep. Most companies score one. Some score zero on the pages that receive the traffic.
Three. Take the two cheapest gaps to regulatory as specific requests
Ask what would be required, not whether it is allowed. Requirements can be met. Permission can be declined without a reason.
Four. Name an owner, with a deliverable and a date
Without this the other three decay within a quarter. Ownership by a named individual is the only step here that survives a reorganization, and it is the one most likely to be skipped because it requires a decision rather than an activity.
Your best-cleared product is losing to weaker evidence because the evidence that decides the sale was never written down. That is fixable, it is fixable this quarter, and the constraint is organizational rather than regulatory.
Frequently Asked Questions
Why do surgeons ignore medical device websites?
Most medical device websites are structured to satisfy regulatory review rather than to answer the questions a surgeon has during evaluation. Surgeons are looking for peer adoption in their specialty, documented failure modes, learning curve cost in operating room time, independent references, and transparent evidence funding. A clearance summary answers none of these.
What is the difference between regulatory content and commercial content in MedTech?
Regulatory content documents what a company claimed and proved and is assessed against the indication for use. Commercial content answers whether adopting the device is worth changing an existing workflow. They serve different readers, require different structures, and are typically produced by different functions. Most companies produce only the first.
Can a MedTech website legally answer surgeon adoption questions?
In most cases yes. Institutional adoption, failure modes already documented in the instructions for use, operational learning curve data, peer references, and study funding disclosure do not typically constitute claims beyond the indication for use. Regulatory constraint is frequently cited to explain a gap far larger than it actually accounts for.
Who should own commercial evidence in a medical device company?
A named individual on the commercial team, with a defined deliverable and a date. When ownership sits with a function rather than a person, the artifact defaults to the most risk-averse position in the review chain, which is regulatory.
How long does a surgeon spend evaluating a device website?
Evaluation typically happens in short sessions between clinical commitments, frequently on a mobile device. The practical implication is that answers must be reachable without navigation depth rather than filed in a resources section.
Should a MedTech company publish its device learning curve?
In most cases yes. Surgeons assume a learning curve exists and will estimate it pessimistically without data, because the cost of underestimating it falls on them. Publishing an honest curve with context removes the largest single adoption objection, and operating time is operational rather than clinical data.
Why does a competitor with weaker clinical evidence win deals?
Because clinical evidence and commercial evidence answer different questions. A competitor that provides peer adoption data, named references, and honest adoption costs is answering the questions that decide the purchase, even where its efficacy data is less strong.
How do you measure the cost of a website that fails the second reader?
Compare close rates on opportunities where a peer reference was requested and provided against those where it was requested and unavailable. Most organizations have never segmented this, and the gap is usually large enough to fund the remedy several times over.
EXTERNAL CITATIONS
•
FDA Premarket Notification 510(k)
•
FDA 510(k) searchable database
•
CMS Open Payments database
